Market closed
Beam Therapeutics/$BEAM
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Beam Therapeutics
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.
Ticker
$BEAM
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
472
Website
BEAM Metrics
BasicAdvanced
$2.3B
Market cap
-
P/E ratio
-$1.75
EPS
1.86
Beta
-
Dividend rate
Price and volume
Market cap
$2.3B
Beta
1.86
52-week high
$49.50
52-week low
$20.84
Average daily volume
1.2M
Financial strength
Current ratio
5.688
Quick ratio
5.569
Long term debt to equity
18.846
Total debt to equity
20.48
Management effectiveness
Return on assets (TTM)
-9.27%
Return on equity (TTM)
-18.29%
Valuation
Price to revenue (TTM)
6.743
Price to book
2.89
Price to tangible book (TTM)
2.89
Price to free cash flow (TTM)
-16.217
Growth
Revenue change (TTM)
328.73%
Earnings per share change (TTM)
-58.25%
3-year revenue growth (CAGR)
664.99%
3-year earnings per share growth (CAGR)
-35.50%
What the Analysts think about BEAM
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Beam Therapeutics stock.
BEAM Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
BEAM Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
BEAM News
AllArticlesVideos
Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual Meeting
GlobeNewsWire·3 weeks ago
Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting
GlobeNewsWire·3 weeks ago
Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer
GlobeNewsWire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Beam Therapeutics stock?
Beam Therapeutics (BEAM) has a market cap of $2.3B as of December 27, 2024.
What is the P/E ratio for Beam Therapeutics stock?
The price to earnings (P/E) ratio for Beam Therapeutics (BEAM) stock is 0 as of December 27, 2024.
Does Beam Therapeutics stock pay dividends?
No, Beam Therapeutics (BEAM) stock does not pay dividends to its shareholders as of December 27, 2024.
When is the next Beam Therapeutics dividend payment date?
Beam Therapeutics (BEAM) stock does not pay dividends to its shareholders.
What is the beta indicator for Beam Therapeutics?
Beam Therapeutics (BEAM) has a beta rating of 1.86. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.